Up next

DCAT Value Chain Insights Bonus Coverage: From DCAT Week 2024: Supplier News Roundup 

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging.

What other DCAT Member Companies are making the news? A roundup of the latest developments from CDMOs/CMOs and other suppliers in drug-substance (small molecules & biologics) and drug-product development and manufacturing and packaging. 

Companies making the news 
Here is a roundup of recent news announcements from DCAT Member Companies across the bio/pharmaceutical manufacturing value chain: from active pharmaceutical ingredients (small molecules and biologics) to drug products (solid dosage, injectables and specialty dosage forms), and packaging.  
 
See related stories and the companies making the news below:   

From DCAT Week 2024: Supplier News: Chemicals/Chemical API Manufacturing
Featuring news from Olon, Grace, PharmaBlock, Axplora, ChemCon, Suven Pharma and The Solubility Company. 

From DCAT Week 2024: Supplier News: Biologics Manufacturing
Featuring news from Siegfried and Solvias. 

From DCAT Week 2024: Supplier News: Formulation Development/Drug Product Manufacturing 
Featuring news from Alcami, Corealis Pharma, Curia, Delpharm and Grand River Aseptic Manufacturing. 

From DCAT Week 2024: Supplier News: End-to-End (Drug Substance and Drug Product)
Featuring news from Lonza and Mabion.  

From DCAT Week 2024: Supplier News: Packaging 
Featuring news from Adare Pharma Solutions and ApiJect 

Recent Feature Articles

What’s in Store for Pharma in 2026 & Beyond?

By
Evolving tariff/trade policy, US drug pricing reforms, and a changing global landscape are contributing to an uncertain environment. A DCAT Week education program, featuring experts from IQVIA, will provide in-depth insights on pharma industry performance. 

Manufacturing Outlook: A Pharma & CDMO View

By
The wave of US pharmaceutical manufacturing investments has garnered the headlines, but are geographic capacity shifts really in the making? A DCAT Week education program will provide expert analysis, including on the all-important, “make-versus-buy” decision.

Blockbuster Contenders: The Class of 2026

By
What new products, recently or expected to launch in 2026, show blockbuster potential or will be transformative in key therapeutic areas? A look at the companies and products rising to the top of the class. 

CDMOs Roll Out Expansions for Parenteral Drugs

By
The global injectables drugs market is projected for strong growth, driven by demand in biologics and specialty therapeutics. In response, CDMOs/CMOS are expanding production capacity. What are the latest expansions?